Bone Biologics Corporation (BBLG)
After hours:
| Previous Close | 1.7200 |
| Open | 1.6500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.6300 - 1.7200 |
| 52 Week Range | 0.8000 - 10.5600 |
| Volume | |
| Avg. Volume | 4,227,659 |
| Market Cap | 3.627M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.2400 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.75 |
- Business Wire
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
BURLINGTON, Mass., October 21, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.
- Business Wire
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGTON, Mass., September 04, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern t
